Being selected as a finalist for a prestigious grant like Merck KGaA's EMEA Advance Biotech Grant is a significant achievement for Theriva Biologics. It suggests recognition of the company's potential and innovation in the biotech field, which can lead to increased investor confidence and a positive impact on the stock price.